| answer text |
<p>On its website, Accelerated Evolution Biotechnologies Ltd presents a technology
platform to identify promising peptides that can target cancer cells. All other information
on multi-target toxin, (MuTaTo), which is a product combining several cancer-targeting
peptides with a strong peptide toxin, which would be personalised to each patient
and kill cancer cells specifically - is derived from interviews to newspapers. As
no publication of the company’s preliminary works (in vitro and in animals) is available
from scientific journals, neither scientific experts nor the Medicines and Healthcare
products Regulatory Agency (MHRA) is able to make any assessment of this therapy.
The company claims that it is about to start clinical trials, but currently, no clinical
trial with such a compound is registered in the European Union public register. If,
in the future, the company wishes to apply for a Marketing Authorisation when results
in patients become available, the MHRA will be able to assess the quality, safety
and efficacy of this therapy and its risk and benefit for its use.</p>
|
|
